Healthcare Market Research Reports & Industry Analysis

Healthcare refers to the field associated with maintaining or restoring patients’ health. These days’ Healthcare Industry falls into a lashing of discrete sub-sectors, and ancillary goods and services. Ranging from therapeutic equipment to medicinal drugs, medical tourism to sickness insurance, the Healthcare Market has been one of the most swiftly expanding sectors within the globe’s economic system.

Global Healthcare spending contributes close to 10% to the whole world’s GDP, though it varies noticeably with geography. Thus, the Western world’s average healthcare costs are far greater in contrast to those in the developing economies. North America alone is in charge of circa a half of the world’s overall spending on healthcare services. With budgets curtailments and growing costs, technology advances are increasingly taking a new meaning in the global Healthcare universe.

The research reports offer comprehensive insights into the market sizing, structure and dynamics of the Healthcare Industry based on various geographies, as well as in-depth market segmentation. The research reports incorporated in this Catalogue closely investigate the competition in the Healthcare Market, besides profiling countless market participants. Moreover, tomorrow's healthcare-related challenges are addressed, as well as projections into the future are provided in the research reports.

Publications found: 71,946
Sort by:

Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) development ...

May 2022 56 pages

1 Phosphatidylinositol 3 Phosphate 5 Kinase (FYVE Finger Containing Phosphoinositide Kinase or Phosphatidylinositol 3 Phosphate 5 Kinase Type III or PIKFYVE or EC 2.7.1.150) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

1 Phosphatidylinositol 3 Phosphate 5 Kinase (FYVE Finger Containing Phosphoinositide Kinase or Phosphatidylinositol 3 Phosphate 5 Kinase Type III or PIKFYVE or EC 2.7.1.150) Drugs in Development by Th...

May 2022 40 pages

3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase (HMG CoA Reductase or Hydroxymethylglutaryl CoA Reductase or HMGCR or EC 1.1.1.34) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase (HMG CoA Reductase or Hydroxymethylglutaryl CoA Reductase or HMGCR or EC 1.1.1.34) Drugs in Development by Therapy Areas and Indications, Stages, MoA, R...

May 2022 73 pages

3-Oxo 5-Alpha Steroid 4 Dehydrogenase 2 (5 Alpha SR2 or Steroid 5 Alpha Reductase 2 or Type II 5 Alpha Reductase or SR Type 2 or SRD5A2 or EC 1.3.1.22) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

3-Oxo 5-Alpha Steroid 4 Dehydrogenase 2 (5 Alpha SR2 or Steroid 5 Alpha Reductase 2 or Type II 5 Alpha Reductase or SR Type 2 or SRD5A2 or EC 1.3.1.22) Drugs in Development by Therapy Areas and Indica...

May 2022 37 pages

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) Drugs in Development...

May 2022 36 pages

Acetylcholinesterase (Acetylcholine Hydrolase or Yt Blood Group or Apoptosis Related Acetylcholinesterase or ACHE or EC 3.1.1.7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Acetylcholinesterase (Acetylcholine Hydrolase or Yt Blood Group or Apoptosis Related Acetylcholinesterase or ACHE or EC 3.1.1.7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA...

May 2022 86 pages

Alpha 1A Adrenergic Receptor (Alpha 1A Adrenoreceptor or Alpha 1C Adrenergic Receptor or Alpha Adrenergic Receptor 1c or ADRA1A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Alpha 1A Adrenergic Receptor (Alpha 1A Adrenoreceptor or Alpha 1C Adrenergic Receptor or Alpha Adrenergic Receptor 1c or ADRA1A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA...

May 2022 39 pages

Amyloid Beta A4 Protein (ABPP or APPI or Alzheimer Disease Amyloid Protein or Amyloid Precursor Protein or Amyloid Beta Precursor Protein or Cerebral Vascular Amyloid Peptide or Prea4 or Protease Nexin II or APP) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 3,500.00

Amyloid Beta A4 Protein (ABPP or APPI or Alzheimer Disease Amyloid Protein or Amyloid Precursor Protein or Amyloid Beta Precursor Protein or Cerebral Vascular Amyloid Peptide or Prea4 or Protease Nexi...

May 2022 149 pages

Angiotensin Converting Enzyme 2 (ACE Related Carboxypeptidase or Metalloprotease MPROT15 or Angiotensin Converting Enzyme Homolog or ACE2 or EC 3.4.17.23) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Angiotensin Converting Enzyme 2 (ACE Related Carboxypeptidase or Metalloprotease MPROT15 or Angiotensin Converting Enzyme Homolog or ACE2 or EC 3.4.17.23) Drugs in Development by Therapy Areas and Ind...

May 2022 50 pages

Apelin Receptor (Angiotensin Receptor Like 1 or G Protein Coupled Receptor APJ or G Protein Coupled Receptor HG11 or APLNR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Apelin Receptor (Angiotensin Receptor Like 1 or G Protein Coupled Receptor APJ or G Protein Coupled Receptor HG11 or APLNR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Mol...

May 2022 41 pages

Apoptosis Associated Speck Like Protein Containing A CARD (Caspase Recruitment Domain Containing Protein 5 or PYD And CARD Domain Containing Protein or Target Of Methylation Induced Silencing 1 or ASC or PYCARD) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Apoptosis Associated Speck Like Protein Containing A CARD (Caspase Recruitment Domain Containing Protein 5 or PYD And CARD Domain Containing Protein or Target Of Methylation Induced Silencing 1 or ASC...

May 2022 40 pages

ATP Binding Cassette Sub Family G Member 2 (Breast Cancer Resistance Protein or Mitoxantrone Resistance Associated Protein or Placenta Specific ATP Binding Cassette Transporter or Urate Exporter or CD338 or ABCG2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

ATP Binding Cassette Sub Family G Member 2 (Breast Cancer Resistance Protein or Mitoxantrone Resistance Associated Protein or Placenta Specific ATP Binding Cassette Transporter or Urate Exporter or CD...

May 2022 37 pages

ATP Sensitive Inward Rectifier Potassium Channel 11 (Potassium Channel Inwardly Rectifying Subfamily J Member 11 or Inward Rectifier Potassium Channel Kir6.2 or KCNJ11) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

ATP Sensitive Inward Rectifier Potassium Channel 11 (Potassium Channel Inwardly Rectifying Subfamily J Member 11 or Inward Rectifier Potassium Channel Kir6.2 or KCNJ11) Drugs in Development by Therapy...

May 2022 35 pages

ATP Sensitive Inward Rectifier Potassium Channel 8 (Inward Rectifier K(+) Channel Kir6.1 or Potassium Channel Inwardly Rectifying Subfamily J Member 8 or uKATP 1 or KCNJ8) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

ATP Sensitive Inward Rectifier Potassium Channel 8 (Inward Rectifier K(+) Channel Kir6.1 or Potassium Channel Inwardly Rectifying Subfamily J Member 8 or uKATP 1 or KCNJ8) Drugs in Development by Ther...

May 2022 35 pages

Atrial Natriuretic Peptide Receptor 1 (Atrial Natriuretic Peptide Receptor Type A or Guanylate Cyclase A or NPR1 or EC 4.6.1.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Atrial Natriuretic Peptide Receptor 1 (Atrial Natriuretic Peptide Receptor Type A or Guanylate Cyclase A or NPR1 or EC 4.6.1.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA,...

May 2022 44 pages

Atrial Natriuretic Peptide Receptor 2 (Atrial Natriuretic Peptide Receptor Type B or Guanylate Cyclase B or NPR2 or EC 4.6.1.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Atrial Natriuretic Peptide Receptor 2 (Atrial Natriuretic Peptide Receptor Type B or Guanylate Cyclase B or NPR2 or EC 4.6.1.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA,...

May 2022 39 pages

Atypical Chemokine Receptor 3 (C-X-C Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Atypical Chemokine Receptor 3 (C-X-C Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3)...

May 2022 35 pages

B Lymphocyte Antigen CD20 (B Lymphocyte Surface Antigen B1 or Bp35 or Leukocyte Surface Antigen Leu 16 or Membrane Spanning 4 Domains Subfamily A Member 1 or CD20 or MS4A1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

B Lymphocyte Antigen CD20 (B Lymphocyte Surface Antigen B1 or Bp35 or Leukocyte Surface Antigen Leu 16 or Membrane Spanning 4 Domains Subfamily A Member 1 or CD20 or MS4A1) Drugs in Development by The...

May 2022 39 pages

Baculoviral IAP Repeat Containing Protein 2 (C IAP1 or IAP Homolog B or Inhibitor Of Apoptosis Protein 2 or RING Finger Protein 48 or TNFR2 TRAF Signaling Complex Protein 2 or BIRC2 or EC 6.3.2.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Baculoviral IAP Repeat Containing Protein 2 (C IAP1 or IAP Homolog B or Inhibitor Of Apoptosis Protein 2 or RING Finger Protein 48 or TNFR2 TRAF Signaling Complex Protein 2 or BIRC2 or EC 6.3.2.) Drug...

May 2022 36 pages

Bifunctional Epoxide Hydrolase 2 (Cytosolic Epoxide Hydrolase 2 or Epoxide Hydratase or Soluble Epoxide Hydrolase or Lipid Phosphate Phosphatase or EPHX2 or EC 3.3.2.10 or EC 3.1.3.76) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Bifunctional Epoxide Hydrolase 2 (Cytosolic Epoxide Hydrolase 2 or Epoxide Hydratase or Soluble Epoxide Hydrolase or Lipid Phosphate Phosphatase or EPHX2 or EC 3.3.2.10 or EC 3.1.3.76) Drugs in Develo...

May 2022 42 pages

Bile Acid Receptor (Farnesoid X Activated Receptor or Farnesol Receptor HRR 1 or Nuclear Receptor Subfamily 1 Group H Member 4 or Retinoid X Receptor Interacting Protein 14 or FXR or NR1H4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Bile Acid Receptor (Farnesoid X Activated Receptor or Farnesol Receptor HRR 1 or Nuclear Receptor Subfamily 1 Group H Member 4 or Retinoid X Receptor Interacting Protein 14 or FXR or NR1H4) Drugs in D...

May 2022 63 pages

C-C Chemokine Receptor Type 8 (CC Chemokine Receptor CHEMR1 or CMKBRL2 or Chemokine Receptor Like 1 or GPR CY6 or TER1 or CDw198 or CCR8) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

C-C Chemokine Receptor Type 8 (CC Chemokine Receptor CHEMR1 or CMKBRL2 or Chemokine Receptor Like 1 or GPR CY6 or TER1 or CDw198 or CCR8) Drugs in Development by Therapy Areas and Indications, Stages,...

May 2022 44 pages

C-C Motif Chemokine 2 (HC11 or Monocyte Chemoattractant Protein 1 or Monocyte Chemotactic And Activating Factor or MCAF or Monocyte Chemotactic Protein 1 or Monocyte Secretory Protein JE or Small Inducible Cytokine A2 or CCL2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

C-C Motif Chemokine 2 (HC11 or Monocyte Chemoattractant Protein 1 or Monocyte Chemotactic And Activating Factor or MCAF or Monocyte Chemotactic Protein 1 or Monocyte Secretory Protein JE or Small Indu...

May 2022 37 pages

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Rece...

May 2022 61 pages

Calpain 1 Catalytic Subunit (Calcium Activated Neutral Proteinase 1 or Calpain Mu Type or Calpain 1 Large Subunit or Cell Proliferation Inducing Gene 30 Protein or Micromolar Calpain or CAPN1 or EC 3.4.22.52) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Calpain 1 Catalytic Subunit (Calcium Activated Neutral Proteinase 1 or Calpain Mu Type or Calpain 1 Large Subunit or Cell Proliferation Inducing Gene 30 Protein or Micromolar Calpain or CAPN1 or EC 3....

May 2022 38 pages

Calpain 2 Catalytic Subunit (Calcium Activated Neutral Proteinase 2 or Calpain M Type or Calpain Large Polypeptide L2 or Calpain 2 Large Subunit or Millimolar Calpain or CANPL2 or CAPN2 or EC 3.4.22.53) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Calpain 2 Catalytic Subunit (Calcium Activated Neutral Proteinase 2 or Calpain M Type or Calpain Large Polypeptide L2 or Calpain 2 Large Subunit or Millimolar Calpain or CANPL2 or CAPN2 or EC 3.4.22.5...

May 2022 41 pages

CD27 Antigen (CD27L Receptor or T Cell Activation Antigen CD27 or Tumor Necrosis Factor Receptor Superfamily Member 7 or T14 or TNFRSF7 or CD27) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

CD27 Antigen (CD27L Receptor or T Cell Activation Antigen CD27 or Tumor Necrosis Factor Receptor Superfamily Member 7 or T14 or TNFRSF7 or CD27) Drugs in Development by Therapy Areas and Indications,...

May 2022 39 pages

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Drugs in Development by Therapy Areas and Indications, Stage...

May 2022 49 pages

Cells Expressing B Cell Receptor CD22 (B Lymphocyte Cell Adhesion Molecule or Sialic Acid Binding Ig Like Lectin 2 or T Cell Surface Antigen Leu 14 or CD22) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing B Cell Receptor CD22 (B Lymphocyte Cell Adhesion Molecule or Sialic Acid Binding Ig Like Lectin 2 or T Cell Surface Antigen Leu 14 or CD22) Drugs in Development by Therapy Areas and I...

May 2022 118 pages

Cells Expressing B Lymphocyte Antigen CD20 (B Lymphocyte Surface Antigen B1 or Bp35 or Leukocyte Surface Antigen Leu 16 or Membrane Spanning 4 Domains Subfamily A Member 1 or CD20 or MS4A1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 3,500.00

Cells Expressing B Lymphocyte Antigen CD20 (B Lymphocyte Surface Antigen B1 or Bp35 or Leukocyte Surface Antigen Leu 16 or Membrane Spanning 4 Domains Subfamily A Member 1 or CD20 or MS4A1) Drugs in D...

May 2022 159 pages

Cells Expressing Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, M...

May 2022 40 pages

Cells Expressing C Type Lectin Domain Family 12 Member A (Myeloid Inhibitory C Type Lectin Like Receptor or Dendritic Cell Associated Lectin 2 or C Type Lectin Like Molecule 1 or CLEC12A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing C Type Lectin Domain Family 12 Member A (Myeloid Inhibitory C Type Lectin Like Receptor or Dendritic Cell Associated Lectin 2 or C Type Lectin Like Molecule 1 or CLEC12A) Drugs in Dev...

May 2022 54 pages

Cells Expressing Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Drugs in Development by Therapy Areas and Indic...

May 2022 59 pages

Cells Expressing CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Drugs in Development by Therapy Areas and I...

May 2022 40 pages

Cells Expressing Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, R...

May 2022 45 pages

Cells Expressing Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1) Drugs in Development by Therapy Areas and...

May 2022 115 pages

Cells Expressing Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1) Drugs in Development by Therapy Areas and...

May 2022 48 pages

Cells Expressing Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protei...

May 2022 99 pages

Cells Expressing Inactive Tyrosine Protein Kinase Transmembrane Receptor ROR1 (Neurotrophic Tyrosine Kinase Receptor Related 1 or ROR1 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Inactive Tyrosine Protein Kinase Transmembrane Receptor ROR1 (Neurotrophic Tyrosine Kinase Receptor Related 1 or ROR1 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indicat...

May 2022 54 pages

Cells Expressing Nectin 4 (Ig Superfamily Receptor LNIR or Poliovirus Receptor Related Protein 4 or Nectin Cell Adhesion Molecule 4 or PVRL4 or NECTIN4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Nectin 4 (Ig Superfamily Receptor LNIR or Poliovirus Receptor Related Protein 4 or Nectin Cell Adhesion Molecule 4 or PVRL4 or NECTIN4) Drugs in Development by Therapy Areas and Indic...

May 2022 46 pages

Cells Expressing NKG2 D Type II Integral Membrane Protein (Killer Cell Lectin Like Receptor Subfamily K Member 1 or NK Cell Receptor D or NKG2D Activating NK Receptor or CD314 or NKG2D or KLRK1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing NKG2 D Type II Integral Membrane Protein (Killer Cell Lectin Like Receptor Subfamily K Member 1 or NK Cell Receptor D or NKG2D Activating NK Receptor or CD314 or NKG2D or KLRK1) Drugs...

May 2022 52 pages

Cells Expressing Receptor Type Tyrosine Protein Kinase FLT3 (FMS Like Tyrosine Kinase 3 or FL Cytokine Receptor or Stem Cell Tyrosine Kinase 1 or Fetal Liver Kinase 2 or CD135 or FLT3 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Receptor Type Tyrosine Protein Kinase FLT3 (FMS Like Tyrosine Kinase 3 or FL Cytokine Receptor or Stem Cell Tyrosine Kinase 1 or Fetal Liver Kinase 2 or CD135 or FLT3 or EC 2.7.10.1)...

May 2022 41 pages

Cells Expressing Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) Drugs in Development...

May 2022 49 pages

Cells Expressing SLAM Family Member 7 (CD319 or Membrane Protein FOAP 12 or CD2 Like Receptor Activating Cytotoxic Cells or Novel Ly9 or Protein 19A or CD2 Subset 1 or CS1 or SLAMF7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing SLAM Family Member 7 (CD319 or Membrane Protein FOAP 12 or CD2 Like Receptor Activating Cytotoxic Cells or Novel Ly9 or Protein 19A or CD2 Subset 1 or CS1 or SLAMF7) Drugs in Developm...

May 2022 44 pages

Cells expressing Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells expressing Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) Drugs in Development by Therapy Areas and Indication...

May 2022 37 pages

Cells Expressing Trophoblast Glycoprotein (M6P1 or 5T4 Oncofetal Antigen or 5T4 Oncofetal Trophoblast Glycoprotein or Wnt Activated Inhibitory Factor 1 or TPBG) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Trophoblast Glycoprotein (M6P1 or 5T4 Oncofetal Antigen or 5T4 Oncofetal Trophoblast Glycoprotein or Wnt Activated Inhibitory Factor 1 or TPBG) Drugs in Development by Therapy Areas a...

May 2022 46 pages

Cells Expressing Tumor Associated Calcium Signal Transducer 2 (Cell Surface Glycoprotein Trop 2 or Membrane Component Chromosome 1 Surface Marker 1 or Pancreatic Carcinoma Marker Protein GA733-1 or TACSTD2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Tumor Associated Calcium Signal Transducer 2 (Cell Surface Glycoprotein Trop 2 or Membrane Component Chromosome 1 Surface Marker 1 or Pancreatic Carcinoma Marker Protein GA733-1 or TA...

May 2022 55 pages

Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17 (B Cell Maturation Antigen or CD269 or BCMA or TNFRSF17) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 3,500.00

Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17 (B Cell Maturation Antigen or CD269 or BCMA or TNFRSF17) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA,...

May 2022 188 pages

Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8 (CD30L Receptor or Ki 1 Antigen or Lymphocyte Activation Antigen CD30 or CD30 or TNFRSF8) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8 (CD30L Receptor or Ki 1 Antigen or Lymphocyte Activation Antigen CD30 or CD30 or TNFRSF8) Drugs in Development by Therapy Areas and...

May 2022 62 pages

Filters

Search

Categories

209
1,199
32
238
214
187
155
140
64,297
1,312
1,311
2,468
184

Publishers

179
1
1,431
239
366
389
103
148
348
3
202
3
6
1,620
487
80
123
208
112
25
1,049
378
23
40
68
510
953
34
29,954
248
501
3,036
1
1
2
3
16
536
361
1
1,357
1,806
60
1,696
8
7,373
2,206
6,709
321
66
3
36
200
29
29
143
42
83
3
281
85
20
6
43
14
1
178
48
359
36
44
10
11
18
168
384
8
3
18
58
907
6
89
12
24
15
1,285
227
128
386
3
74
10
119
227
46
474
26
133
4

Regions

92
58
45
43
41
35
31
30
30
29
28
28
28
26
21
18
16
14
12
12
10
10
10
9
8
8
8
7
7
7
7
6
6
6
6
6
6
6
6
6
6
6
6
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
797
497
2
2
2
118
197
102
54
23
708
26
135
530
177
646
66,872

Price

—

Date

—

Pages

—

Offers

1
280
1
1